Fig. 1. In vitro binding and neutralization activities of C12G6.

Slides:

Advertisements

Similar presentations

“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.

Advertisements

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1. NS1 protein alignment and linear epitope mapping of the 10 antibodies used to run the DENV serotype–specific NS1 rapid tests, pan-DENV NS1 test,

Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.

Epidemiological study of influenza B in Shanghai during the 2009–2014 seasons: implications for influenza vaccination strategy B. Zhao, S. Qin, Z. Teng,

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 4 Bacterial taxonomic groups that discriminate among RYGB-, SHAM-, and WMS-derived samples. Bacterial taxonomic groups that discriminate among RYGB-,

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Synergistic effect of S63845 with lapatinib, trastuzumab, or docetaxel

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 1. IS mediates a hyperthrombotic uremic phenotype in an AHR-dependent manner across CKD stages. IS mediates a hyperthrombotic uremic phenotype in.

Volume 3, Issue 4, Pages (April 2013)

Dot plots of trisomic versus fetal fractions for cohorts 1 and 2

Immunofluorescence staining of virus-infected human placental explants

Identification of bioactive compounds modulating STING activation

Fig. 3. Applying the rapid test to analyze human patient sera.

Volume 19, Issue 6, Pages (June 2016)

Expression of THBS2 in human PanIN tissue and PDAC tumor tissue

Fig. 6. Epitope mapping of C12G6.

Fig. 4. MATE1 transcription in RCC.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 4 Phylogeny of rabies strains isolated during and after the mass vaccination campaign. Phylogeny of rabies strains isolated during and after the mass.

Fig. 2. RT-QuIC testing of sCJD and vCJD brain and skin samples.

Fig. 7. NPs accumulate at sites of vascular obstruction.

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 2 Paralog-selective inhibitors of GSK3α and GSK3β were designed and characterized. Paralog-selective inhibitors of GSK3α and GSK3β were designed and.

Fig. 2. Binding of recombinant full-length Lm-411 to muscle receptors, myotubes, and self-polymerization is enhanced by mag and αLNNd. Binding of recombinant.

Fig. 3. Differential mPFC PV neuron activity during exploratory behaviors in CNTNAP2 KO and WT mice. Differential mPFC PV neuron activity during exploratory.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 7. Inhibitory mechanisms of C12G6.

Fig. 3. H3N2 incidence forecasts based on the cluster model for the Unites States. H3N2 incidence forecasts based on the cluster model for the Unites States.

Rapid development of a DNA vaccine for Zika virus

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 1 A single amino acid difference in the ATP-binding domain of GSK3α and GSK3β results in structural and topological differences. A single amino acid.

Volume 23, Issue 3, Pages (April 2018)

Fig. 1 Effect of preinfection β7Hi CD45RA−CD4+ T cell frequency on HIV acquisition risk in CAPRISA 004 study. Effect of preinfection β7Hi CD45RA−CD4+ T.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus

Fig. 4. Exemplars of two patterns of nosocomial MRSA spread.

by Karin Stettler, Martina Beltramello, Diego A

Fig. 6. CXM correlates with age and growth velocity.

Fig. 5. Mapping of HBV S transcripts from HBeAg-positive and HBeAg-negative chimpanzees. Mapping of HBV S transcripts from HBeAg-positive and HBeAg-negative.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 3 CSF1 is expressed in human melanoma.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 2. Cellular response to FolamiRs in vitro.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 1 Digital microfluidic cartridge and ELISA used for measles and rubella testing. Digital microfluidic cartridge and ELISA used for measles and rubella.

Antibody reactivity against HA1 proteins after vaccination.

Fig. 5. Rises in RSV PRNT during the surveillance period.

HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98%

Fig. 1 General VirScan analysis of the human virome.

Fig. 5. Octet BLI competition assay using D25 and motavizumab.

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses by Chenguang Shen, Junyu Chen, Rui.

Atsushi Yamanaka, Eiji Konishi

Functional characterization of multidonor class antibodies.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Neutralizing activity of mAbs isolated from plasmablasts during acute ZIKV infection in DENV-experienced donors. Neutralizing activity of mAbs isolated.

Presentation transcript:

Fig. 1. In vitro binding and neutralization activities of C12G6. In vitro binding and neutralization activities of C12G6. (A) Dendrogram of all nonredundant, full-length influenza B HA sequences from the National Center for Biotechnology Information (NCBI) Flu database. The Yamagata lineage strains are labeled within blue boxes, the Victoria lineage strains are labeled within red boxes, and the earlier lineage strains (influenza B strains isolated before the 1980s) are labeled within purple boxes. (B) Binding (EC50 ELISA values) of C12G6 antibody to representative purified viruses from the three influenza B lineages. EC50 values above 104 ng/ml (dashed line) were scored as negative. (C) Fifty percent inhibitory concentrations [IC50s (micrograms per milliliter)] of the indicated antibodies against representative strains from the three influenza B lineages were determined by performing HI assays. The values are representative of three independent experiments. The values below 50 μg/ml are color-filled: red, strong reactivity; yellow, moderate reactivity; light blue, weak reactivity; >50, negative reactivity. (D) Average IC50 values of the indicated antibodies were determined from three independent neutralization experiments using a panel of 18 influenza B virus strains, each plotted as a single symbol. The negative control was C5G6, a chimeric influenza A antibody containing a human IgG1 Fc fragment, CA/2009, a control influenza A virus. Full viral strain designations are listed in table S2. Chenguang Shen et al., Sci Transl Med 2017;9:eaam5752 Published by AAAS